Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells

Eun Sang Lee, Kyung Kon Ko, Young Ae Joe, Seok-Gu Kang, Yong Kil Hong

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The alkylating agent temozolomide (TMZ) is an effective drug used for the treatment of malignant gliomas. However, tumor relapse combined with the development of drug resistance remains a significant problem. To clarify the mechanism of the resistance of glioma cells to TMZ chemotherapy, TMZ-resistant glioma cell lines (TR cells) were generated using U373 and U251 human glioma cells, and TMZ-resistance was confirmed via viability and apoptosis assays. The TMZ-resistance of TR cells was not associated with the TMZ-resistance molecule O6-methylguanine-DNA-methyltransferase. Notably, the expression level of signal transducers and activators of transcription 3 (STAT3) and serine 727-phosphorylated STAT3 (pSTAT3-Ser727) was highly increased in TR cells, while that of 705-phosphorylated STAT3 (pSTAT3-Tyr705) was decreased. The inhibition of STAT3 expression by small interfering RNA enhanced TRcell TMZ sensitivity. These results suggest that STAT3 contributes to TMZ-resistance in gliomas and is a potential target for the reversal of TMZ-resistance in patients with a recurrent glioma.

Original languageEnglish
Pages (from-to)115-121
Number of pages7
JournalOncology Letters
Volume2
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

temozolomide
STAT3 Transcription Factor
Drug Resistance
Glioma
Cell Line
Alkylating Agents
Methyltransferases

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Eun Sang ; Ko, Kyung Kon ; Joe, Young Ae ; Kang, Seok-Gu ; Hong, Yong Kil. / Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. In: Oncology Letters. 2011 ; Vol. 2, No. 1. pp. 115-121.
@article{5641df2b6b7c497f821e5349a1a958ac,
title = "Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells",
abstract = "The alkylating agent temozolomide (TMZ) is an effective drug used for the treatment of malignant gliomas. However, tumor relapse combined with the development of drug resistance remains a significant problem. To clarify the mechanism of the resistance of glioma cells to TMZ chemotherapy, TMZ-resistant glioma cell lines (TR cells) were generated using U373 and U251 human glioma cells, and TMZ-resistance was confirmed via viability and apoptosis assays. The TMZ-resistance of TR cells was not associated with the TMZ-resistance molecule O6-methylguanine-DNA-methyltransferase. Notably, the expression level of signal transducers and activators of transcription 3 (STAT3) and serine 727-phosphorylated STAT3 (pSTAT3-Ser727) was highly increased in TR cells, while that of 705-phosphorylated STAT3 (pSTAT3-Tyr705) was decreased. The inhibition of STAT3 expression by small interfering RNA enhanced TRcell TMZ sensitivity. These results suggest that STAT3 contributes to TMZ-resistance in gliomas and is a potential target for the reversal of TMZ-resistance in patients with a recurrent glioma.",
author = "Lee, {Eun Sang} and Ko, {Kyung Kon} and Joe, {Young Ae} and Seok-Gu Kang and Hong, {Yong Kil}",
year = "2011",
month = "1",
day = "1",
doi = "10.3892/ol.2010.210",
language = "English",
volume = "2",
pages = "115--121",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. / Lee, Eun Sang; Ko, Kyung Kon; Joe, Young Ae; Kang, Seok-Gu; Hong, Yong Kil.

In: Oncology Letters, Vol. 2, No. 1, 01.01.2011, p. 115-121.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells

AU - Lee, Eun Sang

AU - Ko, Kyung Kon

AU - Joe, Young Ae

AU - Kang, Seok-Gu

AU - Hong, Yong Kil

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The alkylating agent temozolomide (TMZ) is an effective drug used for the treatment of malignant gliomas. However, tumor relapse combined with the development of drug resistance remains a significant problem. To clarify the mechanism of the resistance of glioma cells to TMZ chemotherapy, TMZ-resistant glioma cell lines (TR cells) were generated using U373 and U251 human glioma cells, and TMZ-resistance was confirmed via viability and apoptosis assays. The TMZ-resistance of TR cells was not associated with the TMZ-resistance molecule O6-methylguanine-DNA-methyltransferase. Notably, the expression level of signal transducers and activators of transcription 3 (STAT3) and serine 727-phosphorylated STAT3 (pSTAT3-Ser727) was highly increased in TR cells, while that of 705-phosphorylated STAT3 (pSTAT3-Tyr705) was decreased. The inhibition of STAT3 expression by small interfering RNA enhanced TRcell TMZ sensitivity. These results suggest that STAT3 contributes to TMZ-resistance in gliomas and is a potential target for the reversal of TMZ-resistance in patients with a recurrent glioma.

AB - The alkylating agent temozolomide (TMZ) is an effective drug used for the treatment of malignant gliomas. However, tumor relapse combined with the development of drug resistance remains a significant problem. To clarify the mechanism of the resistance of glioma cells to TMZ chemotherapy, TMZ-resistant glioma cell lines (TR cells) were generated using U373 and U251 human glioma cells, and TMZ-resistance was confirmed via viability and apoptosis assays. The TMZ-resistance of TR cells was not associated with the TMZ-resistance molecule O6-methylguanine-DNA-methyltransferase. Notably, the expression level of signal transducers and activators of transcription 3 (STAT3) and serine 727-phosphorylated STAT3 (pSTAT3-Ser727) was highly increased in TR cells, while that of 705-phosphorylated STAT3 (pSTAT3-Tyr705) was decreased. The inhibition of STAT3 expression by small interfering RNA enhanced TRcell TMZ sensitivity. These results suggest that STAT3 contributes to TMZ-resistance in gliomas and is a potential target for the reversal of TMZ-resistance in patients with a recurrent glioma.

UR - http://www.scopus.com/inward/record.url?scp=78751484422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751484422&partnerID=8YFLogxK

U2 - 10.3892/ol.2010.210

DO - 10.3892/ol.2010.210

M3 - Article

VL - 2

SP - 115

EP - 121

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -